Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells

Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):91-96. doi: 10.1182/hematology.2023000424.ABSTRACTCD19-specific chimeric antigen receptor (CAR) T-cell therapy has become an integral part of our treatment armamentarium for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). However, despite initial remission rates of greater than 80%, durable remission occurs in only 40% to 50% of patients. In this review we summarize our current knowledge of the role of consolidative hematopoietic cell transplantation in the management of pediatric patients who achieved a minimal residual disease-negative complete response post CD19 CAR T-cell therapy. In addition, we review approaches to enhance effector function CD19 CAR T cells, focusing on how to improve persistence and prevent the emergence of CD19- B-ALL blasts.PMID:38066941 | PMC:PMC10727085 | DOI:10.1182/hematology.2023000424
Source: Hematology ASH Education Program - Category: Hematology Authors: Source Type: research